Abraxis BioScience Announces Date for Second Quarter Financial Results and Investor Conference Call

  
    
  
  
    
      Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global 
      biopharmaceutical company, today announced it will release its 2007 
      second quarter financial results before the market opens on Thursday, 
      August 9, 2007. The company also said that senior management will host 
      an investor conference call that same day at 8:30 a.m. PT/11:30 a.m. ET 
      to review the company�s financial results.
    
    
      The conference call will be available to interested parties through a 
      live audio webcast at www.abraxisbio.com 
      and www.earnings.com. 
      The call will also be archived and accessible at both sites for six 
      months.
    
    
      About Abraxis BioScience, Inc.
    
    
      Abraxis BioScience, Inc. is an integrated global biopharmaceutical 
      company dedicated to meeting the needs of critically ill patients. The 
      company�develops, manufactures and markets one of the broadest 
      portfolios of�injectable products and leverages revolutionary technology 
      such as its nab� platform to�discover 
      and deliver breakthrough therapeutics that transform the treatment of 
      cancer and other life-threatening diseases. The first FDA approved 
      product to use this nab platform, ABRAXANE�, 
      was launched in 2005 for the treatment of metastatic breast cancer. 
      Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For 
      more information about the company and its products, please visit www.abraxisbio.com.